CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.149
https://www.valueinhealthjournal.com/article/S1098-3015(23)03279-5/fulltext
Section Title :
Section Order :
10923
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03279-5&doi=10.1016/j.jval.2023.09.149